RASSF1 and neoplasm: Treatment of (T)GCT cell lines with the demethylating agent 5-aza-2′-deoxycytidine led to an increase in transcript levels of RASSF1A, evidencing the epigenetic silencing of RASSF1A also in this tumor model [43].